ENDOMEDIX, INC.
PLEXimine™ platform technology – precision polysaccharide chemistry enabling in situ formation of dynamic structured medical devices for surgical applications
- Sector
- Medtech
- Headquarters
- MONTCLAIR, NJ
- Latest Form D
- $1.2M, May 2019
- Total capital
- $2.3M
- Federal grants
- $785K
- 2 awards · 2015
- Rank in peer group#3 of 35
- Private capital raised
- $1.5M
- 2 Form D · last May 2019
- 89 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 8 pending · first 2016
- Rank in peer group#5 of 35
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$1.2M
- Federal grantHealth and Human S · Phase II · Hemorrhage Control During Brain Surgery$136K
- Federal grantHealth and Human S · Phase II · Hemorrhage Control During Brain Surgery$649K
- Private capital raisedForm D · SEC · 1st filing$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 35 peers
Line = medianMedtech · Material
- Federal grants#3 · top 9%
- Granted patents#5 · top 14%
- Linked publications#1 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Weiliam ChenResearcherDirectorLinked by 2 patents · $785K in grants as PI
- James R. PastenaDirectorNamed in SEC Form D filings
- John M AbrahamsDirector, PromoterNamed in SEC Form D filings
- Richard OlsonDirectorNamed in SEC Form D filings
- Richard RussoExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 13- PendingMethods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationUSPTOApplication 18778040
- GrantedMethods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationUSPTOUS 12,091,471
- GrantedMethods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationUSPTOUS 11,033,654
Show all 13 patent records
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationJun 12, 2025 · Application 18778040Pending
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationSep 17, 2024 · US 12,091,471Granted
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationJun 15, 2021 · US 11,033,654Granted
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationDec 31, 2019 · US 10,517,988Granted
- Biopolymer System for Tissue SealingMay 17, 2018 · Application 15653966Pending
- Biopolymer System for Tissue SealingAug 15, 2017 · US 9,731,044Granted
- Biopolymer System For Tissue SealingFeb 16, 2016 · US 9,259,434Granted
- Biopolymer System For Tissue SealingApplication PCTUS2008009198Pending
- Biocompatible Adherent Sheet For Tissue SealingApplication PCTUS2008007234Pending
- Biopolymer System For Tissue SealingApplication PCTUS2007062393Pending
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationApplication 62769161Pending
- Composition And Method For Vascular EmbolizationApplication PCTUS2007001606Pending
- Methods And Compositions For Achieving Hemostasis And Stable Blood Clot FormationApplication PCTUS2019062192Pending
Recent research by its founders
- Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity20234 cites
- Combined Hydrogel and Mesenchymal Stem Cell Therapy for Moderate-Severity Disc Degeneration in Goats202045 cites
- Translation of an injectable triple-interpenetrating-network hydrogel for intervertebral disc regeneration in a goat model201788 cites
Related companies, and why
- HELIXBIND, INC.Similar federal contract value in Medtech · null in contracts
- EARLY IS GOOD INC.Similar federal contract value in Medtech · null in contracts
- REVBIO, INC.Similar federal contract value in Medtech · null in contracts
- PHAST CORPSimilar federal contract value in Medtech · null in contracts
- SCION NEUROSTIM, LLCSimilar federal contract value in Medtech · null in contracts
- PROTEAS BIOANALYTICS INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .